Cell and Gene Therapy (CGT) Access Model
Closed Posted
- Opportunity number
- CMS-2P2-25-001
- Agency
-
Centers for Medicare and Medicaid Services
Department of Health and Human Services
- Applications due
- Award size
- Up to $9,550,000
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- State Governments
- Other
- Points of contact
-
- <Unknown> support@grants.gov (800) 518-4726
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
This Notice of Funding Opportunity (NOFO) from the Centers for Medicare & Medicaid Services (CMS) announces the opportunity for state governments, the District of Columbia, and U.S. territories participating in the Medicaid Drug Rebate Program to apply for Cooperative Agreement funding to support their participation in the Cell and Gene Therapy (CGT) Access Model. The 11-year voluntary model aims to improve Medicaid beneficiary access to innovative cell and gene therapies, enhance health outcomes, and reduce healthcare expenditures through a CMS-led approach to developing and administering outcomes-based agreements with manufacturers of FDA-approved gene therapies for sickle cell disease. Applications are due by March 14, 2025, and selected recipients will be notified by July 1, 2025.
Up to $9.55 million in Cooperative Agreement funding may be awarded to each selected recipient over the course of up to 10.5 years, from July 1, 2025 through December 31, 2035. The funding is intended to support state implementation activities and to reward states that take steps to improve equitable access to gene therapy and comprehensive care for Medicaid beneficiaries with sickle cell disease. States must apply to both this NOFO and a separate State Request for Applications to be considered for funding.
Synopsis
2 versions
Update #2 · Latest ·
The Cell & Gene Therapy (CGT) Access Model Notice of Funding Opportunity (NOFO) has been updated. The purpose of this update is to remove outdated language and ensure that the NOFO reflects the new strategic priorities of the CMS Innovation Center. The updates to the NOFO do not have any impact on the amount of funding or permissible activities related to receiving that funding. CMS remains committed to the success of the CGT Access Model and strongly encourages states to apply and take advantage of this opportunity to improve patient choice and access to transformative therapies. Please direct any questions to CGTModel@cms.hhs.gov. States may also arrange a one-on-one meeting with the Model Team using this Calendly link - https://calendly.com/cgtaccessmodel/30min?month=2025-02 -
This Notice of Funding Opportunity (NOFO) announces the opportunity to apply for Cooperative Agreement funding to support States participation in the Cell and Gene Therapy (CGT) Access Model (the CGT Access Model or the Model). Eligible applicants are States, the District of Columbia, and any U.S. territory that participates in the Medicaid Drug Rebate Program (MDRP). A maximum of $9.55 million may be awarded to each Recipient, depending on the number of States that apply for funding, pending availability of funds.
Update #1 ·
This Notice of Funding Opportunity (NOFO) announces the opportunity to apply for Cooperative Agreement funding to support States participation in the Cell and Gene Therapy (CGT) Access Model (the CGT Access Model or the Model). Eligible applicants are States, the District of Columbia, and any U.S. territory that participates in the Medicaid Drug Rebate Program (MDRP). A maximum of $9.55 million may be awarded to each Recipient, depending on the number of States that apply for funding, pending availability of funds.
Files
| File | Type | Posted |
|---|---|---|
| CGT NOFO_08.15.24_FINAL.pdf | ||
| CGT NOFO_Revised_02.18.25.pdf | ||
| CGT NOFO_Revised_02.18.25.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity